



## SEQUENCE LISTING

#11/B  
RECEIVED

OCT 26 2000

TECH CENTER 1600/2900

<110> Nibberling, Hendricus  
Hiemstra, Pieter Sicco  
Van den Barrselaar, Maria Theodora  
Pauwels, Ernest Karl Jacob  
Feitsma, Rolf Ide Johannes

<120> Antimicrobial Peptides Derived From Ubiquicidine

<130> Nibbering et al.

<140> 09/424,815

<141> 2000-04-10

<150> PCT/NL98/00311

<151> 1998-05-29

<150> NL 1006164

<151> 1997-05-29

<160> 9

<170> Microsoft Word 97 SR-2

<210> 1

<211> 59

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: Mammalian

<400> 1

Lys Val His Gly Ser Leu Ala Arg Leu Gly Lys Val Arg Gly Gln Thr  
1 5 10 15

Pro Lys Val Ala Lys Gln Gln Lys Lys Lys Lys Lys Thr Gly Arg Ala  
20 25 30

Lys Arg Arg Met Gln Tyr Asn Arg Arg Phe Val Asn Val Val Pro Thr  
35 40 45

Phe Gly Lys Lys Lys Gly Pro Asn Ala Asn Ser  
50 55

<210> 2

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide 1-18

<400> 2

Lys Val His Gly Ser Leu Ala Arg Ala Gly Lys Val Arg Gly Gln Thr

RECEIVED

OCT 30 2000

TECH CENTER 1600/2900

1 5 10 15

Pro Lys  
18

<210> 3  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: peptide 29-41

<400> 3  
Thr Gly Arg Ala Lys Arg Arg Met Gln Tyr Asn Arg Arg  
1 5 10

<210> 4  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: peptide 18-29

<400> 4  
Lys Val Ala Lys Gln Gln Lys Lys Lys Lys Lys Thr  
1 5 10

<210> 5  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: peptide 18-35

<400> 5  
Lys Val Ala Lys Gln Glu Lys Lys Lys Lys Lys Thr Gly Arg Ala Lys  
1 5 10 15

Arg Arg  
18

<210> 6  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: peptide 18-35  
with D-alanine on both ends

<400> 6  
Ala Lys Val Ala Lys Gln Gln Lys Lys Lys Lys Lys Thr Gly Arg Ala

1 5 10 15  
Lys Arg Arg Ala  
20

<210> 7  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: peptide 29-35

<400> 7  
Thr Gly Arg Ala Lys Arg Arg  
1 5

*Sub*  
*01*  
<210> 8  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: peptide 42-59

<400> 8  
Phe Val Asn Val Val Pro Thr Phe Gly Lys Lys Lys Gly Pro Asn Ala  
1 5 10 15

Asn Ser  
18

<210> 9  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: peptide 36-41

<400> 9  
Met Gln Tyr Asn Arg Arg  
1 5